Aprepitant 0mg + Aprepitant 40mg + Aprepitant 200mg + Oxycodone 0mg, p.o. + Oxycodone 20mg, p.o. + Oxycodone 40mg, p.o. + Oxycodone 0mg, IN + Oxycodone 15mg, IN + Oxycodone 30mg, IN
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Narcotic Abuse
Conditions
Narcotic Abuse
Trial Timeline
Oct 1, 2009 → Apr 1, 2011
NCT ID
NCT00999544About Aprepitant 0mg + Aprepitant 40mg + Aprepitant 200mg + Oxycodone 0mg, p.o. + Oxycodone 20mg, p.o. + Oxycodone 40mg, p.o. + Oxycodone 0mg, IN + Oxycodone 15mg, IN + Oxycodone 30mg, IN
Aprepitant 0mg + Aprepitant 40mg + Aprepitant 200mg + Oxycodone 0mg, p.o. + Oxycodone 20mg, p.o. + Oxycodone 40mg, p.o. + Oxycodone 0mg, IN + Oxycodone 15mg, IN + Oxycodone 30mg, IN is a pre-clinical stage product being developed by Merck for Narcotic Abuse. The current trial status is completed. This product is registered under clinical trial identifier NCT00999544. Target conditions include Narcotic Abuse.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00999544 | Pre-clinical | Completed |
Competing Products
1 competing product in Narcotic Abuse
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + EMBEDA - morphine sulfate/ naltrexone hydrochloride + morphine sulfate CR crushed. | Pfizer | Phase 1 | 32 |